Clinical Trials on Benign Ovarian or Tubal Disease in New Zealand

Total 4546 results

ExcellaBio LLC

Terminated

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

Gastric Cancer | Ovarian Cancer | Breast Cancer Female

United States
Cordgenics, LLC

Active, not recruiting

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Recurrent Ovarian Carcinoma | Platinum-resistant Ovarian Cancer

United States
Rogerio A. Lobo
Integrity Nutraceuticals International

Completed

Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome

United States
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States
CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
Celgene Corporation
Prologue Research International

Terminated

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Ovarian Cancer

United States
MedeonBio, Inc.

Active, not recruiting

Safety and Feasibility of the XFLO Expander System (Mercury) (EXPANDER-1)

Benign Prostatic Hyperplasia

Taiwan, Canada, Australia, Georgia
Daniela Matei, MD
Bayer; Hoosier Cancer Research Network

Terminated

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Ovarian Cancer

United States
Ellipse Technologies, Inc.

Completed

A Retrospective Review of Early Onset Spinal Deformity Patients Treated With the Ellipse MAGEC System

Thoracic Insufficiency Syndrome

Hong Kong, New Zealand, Finland, Turkey, Egypt, Italy, United Kingdom
TVA Medical Inc.

Completed

Novel Endovascular Access Trial (NEAT) (NEAT)

Chronic Kidney Disease

Canada, Australia, New Zealand
GlaxoSmithKline

Completed

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Neoplasms, Ovarian

United States, Australia, Singapore
Tesaro, Inc.
Myriad Genetics, Inc.; Facing Our Risk of Cancer Empowered

Completed

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)

Ovarian Neoplasms | Ovarian Cancer

United States, Canada
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Ovarian Neoplasms

United Kingdom, United States
ModernaTX, Inc.

Terminated

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Ovarian Cancer | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

United States
AstraZeneca

Completed

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Canada
Takeda

Recruiting

A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)

United Kingdom, Denmark
AstraZeneca

Completed

An INternational Frontline Ovarian Cancer Real World Management Study (INFORM)

Ovarian Neoplasms

Australia, Korea, Republic of, Taiwan
CASI Pharmaceuticals, Inc.

Completed

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Ovarian Cancer | Peritoneal Cancer | Fallopian Cancer

United States, Canada
Baxalta now part of Shire

Terminated

Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

United States
Amgen

Terminated

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, Belgium, Germany, Italy, United Kingdom, Canada, Denmark, Switzerland, Hong Kong, Austria, Slovakia, Taiwan, Hungary, France, Singapore, Australia, Poland, New Zealand
Bayer
GlaxoSmithKline

Terminated

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Ovarian Cancer | Advanced Solid Tumors (Excluding Prostate Cancer)

United States
St. Luke's-Roosevelt Hospital Center

Completed

Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers

Obesity

United States
GlaxoSmithKline

Completed

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

Ovarian Cancer | Neoplasms, Ovarian

United States, Canada
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Golfers Against Cancer

Recruiting

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Ovarian Cancer

United States
Antonios Likourezos

Withdrawn

Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres

Benign Prostatic Hyperplasia

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

Ovarian Cancer

United States
Merit Medical Systems, Inc.

Terminated

Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Department of Health and Human Services; Penn... and other collaborators

Active, not recruiting

Estrogen, Diet, Genetics and Endometrial Cancer

Cancer | Ovarian Cancer | Endometrial Cancer | Endometrium | Corpus Uteri

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditions

United States
University of Rochester

Completed

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

Polycystic Ovary Syndrome

United States
AstraZeneca
Merck Sharp & Dohme LLC

Completed

A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer (FLAME)

Advanced Ovarian Cancer

United States
Medifocus, Inc.

Unknown

Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)

Benign Prostate Hyperplasia

United States
National Institute of Diabetes and Digestive and...
Merck Sharp & Dohme LLC; Medtronic; Sanofi-Synthelabo; Diagnostic Ultrasound; Uro...

Terminated

Minimally Invasive Surgical Therapy for BPH (MIST)

Benign Prostatic Hyperplasia

United States
Sonnet BioTherapeutics
Hoffmann-La Roche

Recruiting

Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Advanced Solid Tumor | Platinum-resistant Ovarian Cancer

United States, Australia
Gynecologic Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest... and other collaborators

Terminated

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Ovarian Cancer

United States
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Canada, United States
Duke University
Aventis Pharmaceuticals

Completed

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Ovarian Cancer

United States
AbbVie

Completed

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

United States, Puerto Rico
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
AbbVie
Gynecologic Oncology Group;Australia New Zealand Gynaecological Oncology...

Terminated

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (VELIA)

Ovarian Cancer | Ovarian Neoplasm

United States, Australia, Brazil, Denmark, Israel, Japan, Korea, Republic of, New Zealand, Poland, Spain, United Kingdom
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage... and other conditions

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Advanced Recurrent Ovarian Tumors

United States
Dana-Farber Cancer Institute
Novartis; AstraZeneca

Completed

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Breast Cancer | Ovarian Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States, Japan
Eleison Pharmaceuticals LLC.

Terminated

Safety and Efficacy Study of Glufosfamide in Ovarian Cancer

Ovarian Cancer

United States
Sophiris Bio Corp

Completed

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH (PLUS-1)

Benign Prostatic Hyperplasia

United States, Australia, Canada, Russian Federation, Ukraine, New Zealand
Acrivon Therapeutics
GOG Foundation

Recruiting

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Platinum-resistant Ovarian Cancer | Urothelial Carcinoma | Endometrial Adenocarcinoma

United States
Yale University
R-Pharm-US, LLC

Completed

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States

Clinical Trials on Benign Ovarian or Tubal Disease in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations